The SynchroMed™ II programmable, implantable pump delivers drug to the intrathecal space via an implanted catheter. SynchroMed™ II pumps can be managed using the Control WorkflowSM approach, which is designed to help eliminate systemic opioids and provide effective pain relief.
Targeted drug delivery is a safe, proven, and effective way to manage chronic pain with fewer side effects and lower doses than systemic medication.1
Watch the animation to learn more. (2:24)
The drug enters the pump through the reservoir fill port and passes through the reservoir valve and into the SynchroMed™ II pump reservoir. At normal body temperatures, pressurized gas that is stored below the reservoir expands, exerting pressure on the reservoir. The pressure helps advance the drug into the SynchroMed™ II pump tubing.
The peristaltic action of the SynchroMed™ II pump moves the drug from the pump reservoir, through the pump tubing, check valve, catheter access port, and implanted catheter, to the infusion site.
The catheter access port (CAP) allows injection of the drug into the implanted catheter for drug administration and diagnostic purposes. Drug injected into the CAP bypasses the SynchroMed™ II pump mechanism and goes through the catheter port into the implanted catheter to the infusion site.
Discover the benefits of targeted drug delivery. (4:01) - (04:01)
Learn about trialing and long-term patient management. (8:24) - (08:24)
The SynchroMed™ II Clinician Programmer provides a simple, guided workflow approach to programming SynchroMed™ II intrathecal pumps.
The myPTM™ Personal Therapy Manager works with the SynchroMed™ II pump to help alleviate unpredictable pain.
EfficioTM management software is designed to simplify your pump practice by offering efficient schedule planning, simple drug tracking, historical dosing insights, and on-demand access to reports.
8637-20 (20 mL reservoir)
4 to 7 years
8637-40 (40 mL reservoir)
4 to 7 years
Under specific conditions for 1.5 T and 3.0 T MRI scans. Requires interrogation to confirm pump status.
Requires interrogation to confirm pump status.
Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304-1313.